Key Takeaways
- Johnson & Johnson received FDA clearance for Icotyde, an oral plaque psoriasis medication co-developed with Protagonist Therapeutics (PTGX), triggering a ~4.69% decline in ABBV shares
- The once-daily oral pill represents a significant competitive threat to AbbVie’s immunology cornerstone, Skyrizi
- Wall Street analysts still anticipate Skyrizi sales to climb 23% through FY2026 despite the emerging competition
- Technical indicators show ABBV trading beneath its SMA-20 ($227.73), SMA-50 ($224.27), and hovering near its SMA-200 ($214.95), signaling bearish momentum
- Management issued FY2026 EPS projections of $14.37–$14.57 and unveiled a strategic antibody discovery collaboration with Alloy Therapeutics
Shares of AbbVie (ABBV) tumbled approximately 4.69% during Tuesday’s trading session following the FDA’s authorization of Johnson & Johnson’s (JNJ) Icotyde, a novel plaque psoriasis medication. The regulatory approval sparked concern among shareholders given Skyrizi’s pivotal importance to AbbVie’s revenue strategy in the post-Humira era.
The newly approved treatment, created through a partnership between J&J and Protagonist Therapeutics (PTGX), offers patients a convenient once-daily oral option for managing plaque psoriasis. This positions Icotyde as a formidable challenger to Skyrizi, which represents one of AbbVie’s most crucial immunology assets and revenue generators.
Despite the competitive headwinds, Wall Street researchers maintain confidence in Skyrizi’s prospects. The drug’s superior efficacy data and administration schedule are viewed as competitive differentiators, with forecasts indicating sales growth of 23% through fiscal year 2026.
The stock settled near $212.50 after beginning the session below the previous close of $218.60. Intraday trading saw prices fluctuate between $209.42 and $218.60, demonstrating sustained selling momentum throughout the day.
Chart Analysis Reveals Weakening Momentum
From a technical standpoint, ABBV has fallen below all major moving averages, trading underneath its SMA-20 ($227.73), SMA-50 ($224.27), and marginally beneath its SMA-200 ($214.95). This configuration across timeframes signals broadening weakness.
Momentum indicators across both daily and weekly timeframes indicate selling conditions. The RSI has entered bearish territory, while CCI and BBP metrics suggest oversold conditions with negative price action. The ADX reading remains subdued, indicating the absence of a decisive directional trend, while MACD signals remain neutral.
The immediate support zone to monitor sits at $210.83. A decisive break beneath this threshold could accelerate downward pressure. Upside resistance is positioned at the Ichimoku Kijun level of $227.58.
Traders are monitoring a potential range between $210.83 and $215.22, with some anticipating a possible bounce should price action consolidate near the lower boundary.
The 200-day simple moving average at $214.95 could provide temporary support, though the preponderance of technical evidence suggests continued vulnerability.
Legacy Challenges and Aesthetic Headwinds
The competitive pressure from Icotyde arrives during a challenging period for AbbVie. The pharmaceutical giant continues navigating revenue headwinds stemming from Humira’s patent expiration, while its aesthetic medicine portfolio — featuring products like Juvederm — experiences persistent sales erosion.
Recent quarters have witnessed several institutional investors reducing their ABBV allocations, mirroring evolving market sentiment. Corporate insider transactions have skewed toward selling, with two documented sales over the past quarter and zero purchases.
Balancing these concerns, AbbVie revealed a long-term strategic alliance with Alloy Therapeutics focused on building an enhanced antibody discovery platform. The arrangement features initial payments alongside performance-based milestones, demonstrating ongoing commitment to pipeline development.
The company also provided fiscal 2026 earnings per share guidance ranging from $14.37 to $14.57, suggesting executive confidence in the organization’s fundamental business trajectory.
Consensus analyst price targets indicate a fair value of $251.44, accompanied by a recommendation score of 2.2 — indicating moderate buy sentiment. Institutional ownership remains substantial at 74.71%.
Based on GF Value metrics, ABBV carries an estimated value of $198.80, with current trading levels considered fairly priced relative to fundamentals.
